Heart Failure Clinical Trial

v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

Summary

The purpose of this Phase 1b/2a study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MYK-491 in patients with stable heart failure.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Has stable chronic heart failure with reduced ejection fraction
Has adequate acoustic windows for echocardiography

Key Exclusion Criteria:

Any significant structural cardiac abnormalities on Screening TTE
At Screening, symptomatic hypotension or hypertension or bradycardia.
Routinely scheduled outpatient intravenous (IV) infusions for heart failure (e.g., inotropes, vasodilators [e.g., nesiritide], diuretics) or routinely scheduled ultrafiltration.
Presence of protocol specified laboratory abnormalities at Screening.

Study is for people with:

Heart Failure

Phase:

Phase 1

Estimated Enrollment:

52

Study ID:

NCT03447990

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 17 Locations for this study

See Locations Near You

Jacksonville Center for Clinical Research
Jacksonville Florida, 32216, United States
Prism Reseach
Saint Paul Minnesota, 55102, United States
St. Louis Heart and Vascular Cardiology
Saint Louis Missouri, 63136, United States
Newark Beth Israel Medical Center
Newark New Jersey, 07112, United States
Duke University Medical Center
Durham North Carolina, 27710, United States
Ohio State University Medical Center
Columbus Ohio, 43210, United States
Oregon Health & Science University
Portland Oregon, 97239, United States
University of Pennsylvania Heart and Vascular Center
Philadelphia Pennsylvania, 19104, United States
Tennessee Center for Clinical Trials
Tullahoma Tennessee, 37388, United States
Hopital Europeen Georges-Pompidou
Paris , 75015, France
Charite Research Organization
Berlin , 10117, Germany
Groningen UMC
Groningen , 9713 , Netherlands
D&A Research
Sneek , 8601, Netherlands
Wojewodzki Szpital Specjalistyczny we Wroclawiu, Oddzial Kardiologiczny z Pododdzialem Intensywnego Nadzoru Kardiologicznego i Pododdzialem Leczenia Zaburzen Rytmu Serca
Wrocław , 51-12, Poland
Wojewodzki Szpital Specjalistyczny Im M Kopernika
Łódź , 93-51, Poland
Karolinska University Hospital
Stockholm , 17164, Sweden
Queen Elizabeth University Hospital
Glasgow Scotland, G51 4, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Phase:

Phase 1

Estimated Enrollment:

52

Study ID:

NCT03447990

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.